Home Newsfeeds EF Hutton Reiterates Buy on Jasper Therapeutics, Maintains $6.85 Price Target

EF Hutton Reiterates Buy on Jasper Therapeutics, Maintains $6.85 Price Target

EF Hutton analyst Michael King reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $6.85 price target.

byBenzinga Newsdesk

February 27, 2023

1 minute read

EF Hutton analyst Michael King reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $6.85 price target.

Healthcare Analytics-Focused IQVIA Says 2023 Performance Solid Despite Challenging Macro Environment

By Vandana Singh

February 14, 12:26 PM

IQVIA beats Q4 2023 sales expectations, reporting $3.87 billion (3.5% Y/Y). Adjusted EPS of $2.84 exceeds guidance. IQV's 2023 performance and optimistic 2024 outlook.

IQV

NewAmsterdam Pharma Completes Enrollment In Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib In Patients With Heterozygous Familial Hypercholesterolemia And/Or Established Atherosclerotic Cardiovascular Disease

By Happy Mohamed

July 25, 4:29 PM

-- Exceeded Target Enrollment; Expect to Randomize More Than 2,500 Patients -- -- Topline Results Expected in 2H 2024 – NAARDEN, The Netherlands and MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam

NAMS